839 related articles for article (PubMed ID: 17962468)
1. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats.
Kusari J; Zhou S; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5152-9. PubMed ID: 17962468
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine.
Kusari J; Zhou SX; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1044-51. PubMed ID: 19710406
[TBL] [Abstract][Full Text] [Related]
3. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas.
Murata T; Nakagawa K; Khalil A; Ishibashi T; Inomata H; Sueishi K
Lab Invest; 1996 Apr; 74(4):819-25. PubMed ID: 8606491
[TBL] [Abstract][Full Text] [Related]
4. VEGF-initiated blood-retinal barrier breakdown in early diabetes.
Qaum T; Xu Q; Joussen AM; Clemens MW; Qin W; Miyamoto K; Hassessian H; Wiegand SJ; Rudge J; Yancopoulos GD; Adamis AP
Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2408-13. PubMed ID: 11527957
[TBL] [Abstract][Full Text] [Related]
5. Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector.
Shyong MP; Lee FL; Kuo PC; Wu AC; Cheng HC; Chen SL; Tung TH; Tsao YP
Mol Vis; 2007 Jan; 13():133-41. PubMed ID: 17293777
[TBL] [Abstract][Full Text] [Related]
6. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.
Muranaka K; Yanagi Y; Tamaki Y; Usui T; Kubota N; Iriyama A; Terauchi Y; Kadowaki T; Araie M
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4547-52. PubMed ID: 17003451
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo.
Hattori T; Matsubara A; Taniguchi K; Ogura Y
Curr Eye Res; 2010 Feb; 35(2):146-54. PubMed ID: 20136425
[TBL] [Abstract][Full Text] [Related]
8. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats.
Rota R; Chiavaroli C; Garay RP; Hannaert P
Eur J Pharmacol; 2004 Jul; 495(2-3):217-24. PubMed ID: 15249173
[TBL] [Abstract][Full Text] [Related]
9. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits.
Alikacem N; Yoshizawa T; Nelson KD; Wilson CA
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1561-9. PubMed ID: 10798677
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin protects retinal neurons and glial cells in early-stage streptozotocin-induced diabetic rats.
Zhu B; Wang W; Gu Q; Xu X
Exp Eye Res; 2008 Feb; 86(2):375-82. PubMed ID: 18191124
[TBL] [Abstract][Full Text] [Related]
11. Normalization of retinal vascular permeability in experimental diabetes with genistein.
Nakajima M; Cooney MJ; Tu AH; Chang KY; Cao J; Ando A; An GJ; Melia M; de Juan E
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2110-4. PubMed ID: 11481279
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of a coumarin derivative in diabetic rats.
Bucolo C; Ward KW; Mazzon E; Cuzzocrea S; Drago F
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3846-52. PubMed ID: 19279317
[TBL] [Abstract][Full Text] [Related]
13. Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy.
Zheng Z; Chen H; Xu X; Li C; Gu Q
Exp Eye Res; 2007 Apr; 84(4):745-52. PubMed ID: 17303121
[TBL] [Abstract][Full Text] [Related]
14. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina.
Masuzawa K; Jesmin S; Maeda S; Zaedi S; Shimojo N; Miyauchi T; Goto K
Exp Biol Med (Maywood); 2006 Jun; 231(6):1090-4. PubMed ID: 16741055
[TBL] [Abstract][Full Text] [Related]
15. Captopril ameliorates the decreased Na+,K(+)-ATPase activity in the retina of streptozotocin-induced diabetic rats.
Ottlecz A; Bensaoula T
Invest Ophthalmol Vis Sci; 1996 Jul; 37(8):1633-41. PubMed ID: 8675407
[TBL] [Abstract][Full Text] [Related]
16. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy.
Yang LP; Sun HL; Wu LM; Guo XJ; Dou HL; Tso MO; Zhao L; Li SM
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2319-27. PubMed ID: 19011009
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
Kaji Y; Usui T; Ishida S; Yamashiro K; Moore TC; Moore J; Yamamoto Y; Yamamoto H; Adamis AP
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):858-65. PubMed ID: 17251488
[TBL] [Abstract][Full Text] [Related]
18. Characterization of azurocidin as a permeability factor in the retina: involvement in VEGF-induced and early diabetic blood-retinal barrier breakdown.
Skondra D; Noda K; Almulki L; Tayyari F; Frimmel S; Nakazawa T; Kim IK; Zandi S; Thomas KL; Miller JW; Gragoudas ES; Hafezi-Moghadam A
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):726-31. PubMed ID: 18235021
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group.
Barber AJ; Antonetti DA; Gardner TW
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3561-8. PubMed ID: 11006253
[TBL] [Abstract][Full Text] [Related]
20. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats.
Bursell SE; Takagi C; Clermont AC; Takagi H; Mori F; Ishii H; King GL
Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2711-20. PubMed ID: 9418723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
